A High Serum Matrix Metalloproteinase-2 Level Is Associated with an Adverse Prognosis in Node-Positive Breast Carcinoma

Clinical Cancer Research

Volumn 10, Issue 3, 2004, Pages 1057-1063

  Leppä, Sirpa ^a,b   Saarto, Tiina ^a   Vehmanen, Leena ^a   Blomqvist, Carl ^a,c   Elomaa, Inkeri ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; GELATINASE A; GELATINASE B; PROGESTERONE RECEPTOR; TAMOXIFEN; TOREMIFENE;

ADULT; ARTICLE; BONE METASTASIS; BREAST CARCINOMA; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; ENZYME ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PREDICTION; PREMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE DIAGNOSIS; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TUMOR VOLUME; VISCERAL METASTASIS;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BONE NEOPLASMS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TAMOXIFEN; TIME FACTORS; TOREMIFENE; TREATMENT OUTCOME;

EID: 1042290312     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-03-0047     Document Type: Article

References (39)

1. Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., and McGuire, W. L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (Wash. DC), 235: 177-182, 1987.
2. Toikkanen, S., Helin, H., Isola, J., and Joensuu, H. Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up. J. Clin. Oncol., 10: 1044-1048, 1992.
3. Gusterson, B. A., Gelber, R. D., Goldhirsch, A., Price, K. N., Save-Soderborgh, J., Anbazhagan, R., Styles, J., Rudenstam, C. M., Golouh, R., and Reed, R. Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J. Clin. Oncol., 10: 1049-1056, 1992.
4. Paik, S., Bryant, J., Park, C., Fisher, B., Tan-Chiu, E., Hyams, D., Fisher, E. R., Lippman, M. E., Wickerham, D. L., and Wolmark, N. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J. Natl. Cancer Inst., 90: 1361-1370, 1998.
5. Thor, A. D., Moore, D. H., II, Edgerton, S. M., Kawasaki, E. S., Reihsaus, E., Lynch, H. T., Marcus, J. N., Schwartz, L., Chen, L. C., and Mayall, B. H. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J. Natl. Cancer Inst., 84: 845-855, 1992.
6. Turner, B. C., Gumbs, A. A., Carbone, C. J., Carter, D., Glazer, P. M., and Haffty, B. G. Mutant p53 protein overexpression in women with ipsilateral breast tumor recurrence following lumpectomy and radiation therapy. Cancer (Phila.), 88: 1091-1098, 2000.
7. Linderholm, B., Grankvist, K., Wilking, N., Johansson, M., Tavelin, B., and Henriksson, R. Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment. J. Clin. Oncol., 18: 1423-1431, 2000.
8. Keyomarsi, K., Tucker, S. L., Buchholz, T. A., Callister, M., Ding, Y., Hortobagyi, G. N., Bedrosian, I., Knickerbocker, C., Toyofuku, W., Lowe, M., Herliczek, T. W., and Bacus, S. S. Cyclin E and survival in patients with breast cancer. N. Engl. J. Med., 347: 1566-1575, 2002.
9. Shek, L. L., and Godolphin, W. Model for breast cancer survival: relative prognostic roles of axillary nodal status, TNM stage, estrogen receptor concentration, and tumor necrosis. Cancer Res., 48: 5565-5569, 1988.
10. Shek, L. L., and Godolphin, W. Survival with breast cancer: the importance of estrogen receptor quantity. Eur. J. Cancer Clin. Oncol., 25: 243-250, 1989.
11. Skoog, L., Humla, S., Axelsson, M., Frost, M., Norman, A., Nordenskjold, B., and Wallgren, A. Estrogen receptor levels and survival of breast cancer patients. A study on patients participating in randomized trials of adjuvant therapy. Acta Oncol., 26: 95-100, 1987.
12. Ferno, M., Baldetorp, B., Bendahl, P. O., Borg, A., Ewers, S. B., Olsson, H., Ryden, S., Sigurdsson, H., and Killander, D. Recurrence-free survival in breast cancer improved by adjuvant tamoxifen-especially for progesterone receptor positive tumors with a high proliferation. Breast Cancer Res. Treat., 36: 23-34, 1995.
13. Raemaekers, J. M., Beex, L. V., Pieters, G. F., Smals, A. G., Benraad, T. J., and Kloppenborg, P. W. Progesterone receptor activity and relapse-free survival in patients with primary breast cancer: the role of adjuvant chemotherapy. Breast Cancer Res. Treat., 9: 191-199, 1987.
14. Westermarck, J., and Kahari, V. M. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J., 13: 781-792, 1999.
15. Bissell, M. J., and Radisky, D. Putting tumours in context. Nat. Rev. Cancer, 1: 46-54, 2001.
16. Sternlicht, M. D., and Werb, Z. How matrix metalloproteinases regulate cell behavior. Ann. Rev. Cell Dev. Biol., 17: 463-516, 2001.
17. Talvensaari-Mattila, A., Paakko, P., Hoyhtya, M., Blanco-Sequeiros, G., and Turpeenniemi-Hujanen, T. Matrix metalloproteinase-2 immunoreactive protein- A marker of aggressiveness in breast carcinoma. Cancer (Phila.), 83: 1153-1162, 1998.
18. Talvensaari-Mattila, A., Paakko, P., and Turpeenniemi-Hujanen, T. MMP-2 positivity and age less than 40 years increases the risk for recurrence in premenopausal patients with node-positive breast carcinoma. Breast Cancer Res. Treat., 58: 287-293, 1999.
19. Talvensaari-Mattila, A., Paakko, P., Blanco-Sequeiros, G., and Turpeenniemi-Hujanen, T. Matrix metalloproteinase-2 (MMP-2) is associated with the risk for a relapse in postmenopausal patients with node-positive breast carcinoma treated with antiestrogen adjuvant therapy. Breast Cancer Res. Treat., 65: 55-61, 2001.
20. Sheen-Chen, S. M., Chen, H. S., Eng, H. L., Sheen, C. C., and Chen, W. J. Serum levels of matrix metalloproteinase 2 in patients with breast cancer. Cancer Lett., 173: 79-82, 2001.
21. Saarto, T., Blomqvist, C., Virkkunen, P., and Elomaa, I. Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. J. Clin. Oncol., 19: 10-17, 2001.
22. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet, 351: 1451-1467, 1998.
23. Vihinen, P., and Kahari, V. M. Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int. J. Cancer, 99: 157-166, 2002.
24. Hirvonen, R., Talvensaari-Mattila, A., Paakko, P., and Turpeenniemi-Hujanen, T. Matrix metalloproteinase-2 (MMP-2) in T(1-2)N0 breast carcinoma. Breast Cancer Res. Treat., 77: 85-91, 2003.
25. Gohji, K., Fujimoto, N., Komiyama, T., Fujii, A., Ohkawa, J., Kamidono, S., and Nakajima, M. Elevation of serum levels of matrix metalloproteinase-2 and -3 as new predictors of recurrence in patients with urothelial carcinoma. Cancer (Phila.), 78: 2379-2387, 1996.
26. Garzetti, G. G., Ciavattini, A., Lucarini, G., Goteri, G., de e Nictolis, M., Garbisa, S., Masiero, L., Romanini, C., and Graziella, B. Tissue and serum metalloproteinase (MMP-2) expression in advanced ovarian serous cystoadenocarcinomas: clinical and prognostic implications. Anticancer Res., 15: 2799-2804, 1995.
27. Oberg, A., Hoyhtya, M., Tavelin, B., Stenling, R., and Lindmark, G. Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer. Anticancer Res., 20: 1085-1091, 2000.
28. Sasaki, H., Yukiue, H., Kobayashi, Y., Kaji, M., Kiriyama, M., Fukai, I., Yamakawa, Y., and Fujii, Y. Elevated serum pro-MMP2 levels in patients with stage IV thymoma. Surg. Today, 32: 482-486, 2002.
29. Gohji, K., Fujimoto, N., Ohkawa, J., Fujii, A., and Nakajima, M. Imbalance between serum matrix metalloproteinase-2 and its inhibitor as a predictor of recurrence of urothelial cancer. Br. J. Cancer, 77: 650-655, 1998.
30. Wollina, U., Hipler, U. C., Knoll, B., Graefe, T., Kaatz, M., and Kirsch, K. Serum matrix metalloproteinase-2 in patients with malignant melanoma. J. Cancer Res. Clin. Oncol., 127: 631-635, 2001.
31. Sasaki, H., Kiriyama, M., Fukai, I., Yamakawa, Y., and Fujii, Y. Elevated serum pro-mMP2 levels in patients with advanced lung cancer are not suitable as a prognostic marker. Surg. Today, 32: 93-95, 2002.
32. Hanke, B., Wein, A., Martus, P., Riedel, C., Voelker, M., Hahn, E. G., and Schuppan, D. Serum markers of matrix turnover as predictors for the evolution of colorectal cancer metastasis under chemotherapy. Br. J. Cancer, 88: 1248-1250, 2003.
33. Fisher, B., Redmond, C., Poisson, R., Margolese, R., Wolmark, N., Wickerham, L., Fisher, E., Deutsch, M., Caplan, R., Pilch, Y., et al. Eight-year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer. N. Engl. J. Med., 320: 822-828, 1989.
34. Fisher, B., Anderson, S., Fisher, E. R., Redmond, C., Wickerham, D. L., Wolmark, N., Mamounas, E. P., Deutsch, M., and Margolese, R. Significance of ipsilateral breast tumour recurrence after lumpectomy. Lancet, 338: 327-331, 1991.
35. Veronesi, U., Marubini, E., Del Vecchio, M., Manzari, A., Andreola, S., Greco, M., Luini, A., Merson, M., Saccozzi, R., Rilke, F., et al. Local recurrences and distant metastases after conservative breast cancer treatments: partly independent events. J. Natl. Cancer Inst., 87: 19-27, 1995.
36. Poulsom, R., Hanby, A. M., Pignatelli, M., Jeffery, R. E., Longcroft, J. M., Rogers, L., and Stamp, G. W. Expression of gelatinase A and TIMP-2 mRNAs in desmoplastic fibroblasts in both mammary carcinomas and basal cell carcinomas of the skin. J. Clin. Pathol., 46: 429-436, 1993.
37. Polette, M., Nawrocki, B., Pintiaux, A., Massenat, C., Maquoi, E., Volders, L., Schaaps, J. P., Birembaut, P., and Foidart, J. M. Expression of gelatinases A and B and their tissue inhibitors by cells of early and term human placenta and gestational endometrium. Lab. Investig., 71: 838-846, 1994.
38. Brummer, O., Athar, S., Riethdorf, L., Loning, T., and Herbst, H. Matrix-metalloproteinases 1, 2, and 3 and their tissue inhibitors 1 and 2 in benign and malignant breast lesions: an in situ hybridization study. Virchows Arch., 435: 566-573, 1999.
39. Ueno, H., Nakamura, H., Inoue, M., Imai, K., Noguchi, M., Sato, H., Seiki, M., and Okada, Y. Expression and tissue localization of membrane-types 1, 2, and 3 matrix metalloproteinases in human invasive breast carcinomas. Cancer Res., 57: 2055-2060, 1997.